Lucía Gutiérrez-Chamorro, Eudald Felip, Eva Castellà, Vanessa Quiroga, Ifeanyi Jude Ezeonwumelu, Laura Angelats, Anna Esteve, Laia Perez-Roca, Anna Martínez-Cardús, Pedro Luis Fernandez, Angelica Ferrando-Díez, Anna Pous, Milana Bergamino, Beatriz Cirauqui, Marga Romeo, Iris Teruel, Ricard Mesia, Bonaventura Clotet, Eva Riveira-Muñoz, Mireia Margelí, Ester Ballana
PURPOSE: The lack of validated surrogate biomarkers is still an unmet clinical need in the management of early breast cancer cases that do not achieve complete pathological response after neoadjuvant chemotherapy (NACT). Here, we describe and validate the use of SAMHD1 expression as a prognostic biomarker in residual disease in vivo and in vitro. METHODS: SAMHD1 expression was evaluated in a clinical cohort of early breast cancer patients with stage II-III treated with NACT...
September 4, 2023: Cellular Oncology (Dordrecht)